Research analysts at HC Wainwright initiated coverage on shares of Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) in a research note issued on Monday. The firm set a “buy” rating and a $5.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 75.27% from the stock’s current price.

Separately, Rodman & Renshaw began coverage on shares of Imprimis Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $5.00 target price on the stock.

Shares of Imprimis Pharmaceuticals (NASDAQ:IMMY) remained flat at $2.94 during trading on Monday. The company had a trading volume of 97,151 shares. The stock’s market capitalization is $38.96 million. The company has a 50 day moving average of $2.78 and a 200 day moving average of $3.61. Imprimis Pharmaceuticals has a 12-month low of $2.22 and a 12-month high of $7.81.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this report can be read at https://www.thecerbatgem.com/2016/11/29/imprimis-pharmaceuticals-inc-immy-coverage-initiated-at-hc-wainwright.html.

Hedge funds have recently modified their holdings of the company. Northern Trust Corp boosted its stake in shares of Imprimis Pharmaceuticals by 4.1% in the third quarter. Northern Trust Corp now owns 45,467 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 1,800 shares in the last quarter. Granite Investment Partners LLC boosted its stake in shares of Imprimis Pharmaceuticals by 3.7% in the third quarter. Granite Investment Partners LLC now owns 160,876 shares of the specialty pharmaceutical company’s stock valued at $613,000 after buying an additional 5,686 shares in the last quarter. Berson & Corrado Investment Advisors LLC boosted its stake in shares of Imprimis Pharmaceuticals by 6.4% in the third quarter. Berson & Corrado Investment Advisors LLC now owns 33,097 shares of the specialty pharmaceutical company’s stock valued at $126,000 after buying an additional 1,990 shares in the last quarter. Opaleye Management Inc. boosted its stake in shares of Imprimis Pharmaceuticals by 1.4% in the second quarter. Opaleye Management Inc. now owns 1,267,500 shares of the specialty pharmaceutical company’s stock valued at $4,766,000 after buying an additional 17,500 shares in the last quarter. Finally, BlackRock Fund Advisors boosted its stake in shares of Imprimis Pharmaceuticals by 59.5% in the second quarter. BlackRock Fund Advisors now owns 32,979 shares of the specialty pharmaceutical company’s stock valued at $124,000 after buying an additional 12,300 shares in the last quarter. 24.85% of the stock is currently owned by institutional investors and hedge funds.

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

5 Day Chart for NASDAQ:IMMY

Receive News & Stock Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.